Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Treasury Shares (2021 - 2025)

Prime Medicine filings provide 5 years of Treasury Shares readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Treasury Shares changed 0.0% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 0.0% change, with the full-year FY2025 number at $3.5 million, changed 0.0% from a year prior.
  • Treasury Shares hit $3.5 million in Q4 2025 for Prime Medicine, roughly flat from $3.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $5.0 million in Q4 2022 to a low of $3116.0 in Q2 2022.
  • Median Treasury Shares over the past 5 years was $3.5 million (2024), compared with a mean of $2.6 million.
  • Biggest five-year swings in Treasury Shares: soared 73970.51% in 2023 and later crashed 97.58% in 2024.
  • Prime Medicine's Treasury Shares stood at $4.6 million in 2021, then increased by 10.14% to $5.0 million in 2022, then dropped by 23.57% to $3.8 million in 2023, then fell by 9.4% to $3.5 million in 2024, then changed by 0.0% to $3.5 million in 2025.
  • The last three reported values for Treasury Shares were $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $3.5 million (Q2 2025) per Business Quant data.